Ubrelvy (Ubrogepant)

Name: Ubrelvy
Brand: Abbvie
SKU: 7749
Availability: InStock

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

Type:

Product: Ubrelvy Tablet

Manufacturer: Abbvie

Country: Canada

Dosage: 50 mg

Qty-Price (USD):

Type:

Product: Ubrelvy Tablet

Manufacturer: Abbvie

Country: Canada

Dosage: 100 mg

Qty-Price (USD):

Generic Equivalent of Ubrelvy

Type

Product

Manufacturer

Country

Dosage

Qty-Price (USD)

There is no generic product of Ubrelvy.

Ubrelvy Information

medically reviewed by Carol Hou (BSc. Pharm) on December 17, 2025.

A licensed pharmacist (Licensed Community Pharmacies Directory | College of Pharmacists of British Columbia) with over 20 years of experience in medication management, specifically medication safety, she has reviewed the information for accuracy and completeness.

Ubrelvy at CanadaPharmacyOnline.com

Ubrelvy is manufactured and marketed by AbbVie in Canada.

Generic ubrogepant is currently unavailable at this pharmacy.

Dosage:

Ubrelvy is available only in 100 mg strength tablets.

Your doctor will determine the appropriate dose based on your individual needs and medical history.

Usage:

Ubrelvy (Ubrogepant) is an oral medication used to treat acute migraine attacks in adults, meaning it is taken as needed to stop a migraine once it has started, not for daily prevention. A migraine is a neurological condition that causes severe headaches along with other symptoms, such as sensitivity to light and touch, vomiting, and speech difficulties.

Mechanism of Action:
Ubrelvy (ubrogepant) is a targeted migraine medication known as a CGRP receptor antagonist. Its mechanism works by blocking the activity of Calcitonin Gene-Related Peptide (CGRP), a small protein (neuropeptide) released during a migraine attack that significantly contributes to pain and inflammation. Ubrelvy does this by binding directly to the CGRP receptors on nerve endings and blood vessels. By "plugging" these receptors, it prevents the pain-signaling neuropeptide CGRP from binding to and activating those pathways. This interrupts the transmission of migraine pain signals and stops the swelling of blood vessels without causing them to narrow (constriction), which is a common safety concern with older classes of migraine drugs like triptans.

Take Ubrelvy exactly as your doctor prescribes, following the instructions in the product monograph in Canada. Consult your doctor for personalized guidance and safe use.

The information below summarizes some, but not all, potential side effects, risks, and interactions. Before taking Ubrelvy, it is essential to discuss all possible side effects, risks, and interactions with your doctor or pharmacist.

Side Effects:

The information below is a partial list of side effects; individual reactions can vary. Before starting Ubrelvy, it is crucial to discuss potential side effects and risks with your doctor or pharmacist.

Common Side Effects – The following are common side effects of Ubrelvy; other side effects may also occur. Contact your doctor promptly if any side effects persist, worsen, or concern you, or if you experience any other concerning symptoms.
• Nausea (This was the most common side effect.)
• Sleepiness (You may feel unusually drowsy after taking a dose.)

Other Potential Side Effects (less common):
• Dry mouth
• Fatigue (Feeling unusually tired or weak)

Serious Side Effects: These are rare but potentially severe. Seek immediate medical attention or call emergency services if you experience any of the following:
• Anaphylaxis: A life-threatening allergic reaction.
• Breathing Issues: Shortness of breath or trouble breathing.
• Severe Swelling: Swelling of the face, mouth, tongue, or throat.
• Skin Reactions: A severe rash or hives.

Postmarketing Safety Note Some reports involving CGRP-class medications have indicated the development or worsening of high blood pressure (hypertension) and Raynaud's phenomenon (a circulation issue causing numbness or color changes in fingers and toes). If you notice a spike in blood pressure or new circulation problems, contact your healthcare provider.

Contraindications:

The following is not an exhaustive list of contraindications. Before starting Ubrelvy, it is crucial to discuss all your medical conditions, past and present, and all medications you are taking with your doctor or pharmacist.

Do not take Ubrelvy/Ubrogepant if you have the following conditions:
• Allergy or Hypersensitivity: You have a known allergy or hypersensitivity to ubrogepant or any of its ingredients. If you have experienced symptoms such as facial, lip, or tongue swelling or difficulty breathing, you should avoid this medication.
• End-Stage Renal Disease (ESRD): Ubrelvy has not been studied in and is not recommended for patients with end-stage renal disease (defined as a creatinine clearance of less than 15 mL/min).
• Strong CYP3A4 Inhibitor Use: You are taking a potent CYP3A4 inhibitor. Examples include certain antifungal medications (like ketoconazole or itraconazole), certain antibiotics (like clarithromycin), or ritonavir-containing medications used for HIV or Hepatitis C. This combination is strictly avoided because it significantly increases plasma Ubrelvy levels, thereby increasing the risk of severe adverse effects.

Tell your doctor about all of your medical conditions, past and present, before starting Ubrelvy. This is crucial as certain conditions affect the drug’s safety.
• Cardiovascular disease (heart problems or stroke history), as safety data is limited in patients with recent cardiovascular events.
• Hepatic impairment (severe liver problems).
• Renal impairment (severe kidney problems).

Drug Interactions:

Before taking Ubrelvy, discuss all potential risks and interactions with your doctor or pharmacist. For complete and up-to-date information, refer to the official product monograph from AbbVie at https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/UBRELVY_PM_EN.pdf.

Provide your doctor with a complete list of all your medications, including prescriptions, over-the-counter (OTC) drugs, vitamins, herbal supplements, recreational drugs, and any significant dietary changes, as these may interact with Ubrelvy. Ubrelvy may interact with other medicines, but is not limited to:

• Interactions that Increase Ubrelvy Levels (Risk of Side Effects)
o Moderate/Weak CYP3A4 Inhibitors: These require a dose adjustment (typically a lower starting dose of Ubrelvy and limiting the second dose). These include certain heart medications (such as verapamil and diltiazem), some antibiotics (such as ciprofloxacin), and grapefruit/grapefruit juice.
o Strong CYP3A4 Inhibitors (Contraindicated): Concurrent use with these is strictly avoided and is a contraindication. These include Certain antifungal medications (such as ketoconazole and itraconazole), certain antibiotics (such as clarithromycin), and some HIV/Hepatitis C medications (including ritonavir-containing products such as Paxlovid).

• Interactions that Decrease Ubrelvy Levels (Risk of Reduced Effectiveness)
o Strong CYP3A4 Inducers: Concomitant use with these is generally avoided because Ubrelvy may not work at all. These include certain anti-seizure medications (such as phenytoin and carbamazepine), the antibiotic rifampin, and the herbal supplement St. John's Wort.

Pregnancy and Breastfeeding:

Ubrelvy (ubrogepant) is not generally recommended during pregnancy or breastfeeding because there is not enough human data to confirm its safety for the developing baby or nursing infant. Although animal studies did not indicate harm, the potential risks remain uncertain. Healthcare providers usually advise using Ubrelvy during these periods only when the need to treat a mother's acute migraine greatly outweighs the possible, but unknown, risks to the child.

Use in Children:

Ubrelvy (ubrogepant) is not currently approved for use in children or adolescents as a treatment for acute migraine. The medication is explicitly intended for adults, and its safety and effectiveness in patients under 18 years of age have not yet been established through clinical studies. Therefore, Ubrelvy should not be given to pediatric populations.

Frequently Asked Questions about Ubrevly at Canada Pharmacy Online:

Why is Ubrevly more affordable in Canada than in the United States?

Prescription drug prices, including Ubrelvy, are generally lower in Canada than in the US due to a combination of factors, primarily government price regulations, differing market dynamics, and other economic considerations. In Canada, provincial and federal governments negotiate drug prices with pharmaceutical companies, which often results in lower prices than in the US, where market forces play a more significant role. For more information, see the FAQs on Prescription Drug Importation from the Kaiser Family Foundation (KFF): https://www.kff.org/health-costs/issue-brief/faqs-on-prescription-drug-importation/.

How much is the shipping?

Our shipping fee is a flat rate of $10.00 per order. Our pharmacy is dedicated to offering you the lowest prices on high-quality products.

How do I place an order with your pharmacy?

Ordering from us is very simple. You can purchase online or call Customer Service at 1866.920.3784; for more information or to learn about the ordering process, visit our How to Order page.

Do you ship to the United States?

Yes, we do. It usually takes between 7 and 18 business days to receive your order from our pharmacy.

Is there a limit on how many Ubrelvy tablets I can order at one time?

CanadaPharmacyOnline.com can dispense up to a three-month supply of Ubrelvy per your doctor's prescription.

Can I buy Ubrelvy over the counter from you?

No, Ubrelvy requires a valid prescription from your doctor. We do not sell this product without a valid prescription.

Is there a generic for Ubrelvy?

No, there is no generic available for this product.

Blog Post

Suffering From Migraines? Make Sure You’re Not Deficient in This Important Mineral
Ubrelvy vs. Imitrex for Migraine Treatment: Which One Is Best for You in 2024?

Latest News:

The Cognitive Toll of Digital Overuse on Migraine in Young Adults (article published on December 14, 2025)

Similar Drugs in the category of Migraine Medication:

Imitrex Frova Relpax Maxalt Zomig Nasal Spray

The information on this page is sourced from independent third parties contracted by CanadaPharmacyOnline. While we cannot guarantee its medical accuracy, we strongly recommend consulting a healthcare professional for personalized advice regarding medications or medical conditions.

Reviews From Real Customers